Daol Investment & Securities analyzed on the 19th that Boronoi is expected to release interim results of its Phase 1 clinical trial, which could demonstrate its technological capabilities. No investment opinion or target price was provided.
Boronoi is a company with strengths in drug design, developing genotype-directed cancer (GDC) drugs targeting cancers with identified causes. It is the only company in Korea to have built selectivity profile data for 4,000 compounds targeting approximately 500 protein kinases, using this data to derive substances that bind to various targets.
VRN11 plans to conduct a Phase 1 clinical trial involving about 50 non-small cell lung cancer patients at 10 institutions in Korea, the United States, and Taiwan. The IND for the domestic Phase 1 trial was submitted in June 2023, and the trial is expected to commence within the year.
Jisoo Lee, a researcher at Daol Investment & Securities, stated, "The non-small cell lung cancer treatment VRN11 is a next-generation kinase inhibitor targeting the resistance mutation C797S that arises after Tagrisso treatment." He added, "According to preclinical results presented at the WCLC in September, VRN11 completely reduced tumor size at a faster rate than first-generation Iressa and Tasigna, as well as third-generation Tagrisso, at all doses."
Regarding 'VRN07 (ORIC-114)', which Boronoi licensed to ORIC Pharmaceuticals, interim Phase 1 clinical trial results are expected to be announced within the year. He emphasized, "With the announcement of Boronoi's first human clinical trial results, demonstrating efficacy and safety, market entry as a best-in-class drug is anticipated," and "depending on clinical outcomes, it is expected that technological capabilities can be proven."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
